Genome Biology (May 2017)
N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration
- Isidore Rigoutsos,
- Sang Kil Lee,
- Su Youn Nam,
- Simone Anfossi,
- Barbara Pasculli,
- Martin Pichler,
- Yi Jing,
- Cristian Rodriguez-Aguayo,
- Aristeidis G. Telonis,
- Simona Rossi,
- Cristina Ivan,
- Tina Catela Ivkovic,
- Linda Fabris,
- Peter M. Clark,
- Hui Ling,
- Masayoshi Shimizu,
- Roxana S. Redis,
- Maitri Y. Shah,
- Xinna Zhang,
- Yoshinaga Okugawa,
- Eun Jung Jung,
- Aristotelis Tsirigos,
- Li Huang,
- Jana Ferdin,
- Roberta Gafà,
- Riccardo Spizzo,
- Milena S. Nicoloso,
- Anurag N. Paranjape,
- Maryam Shariati,
- Aida Tiron,
- Jen Jen Yeh,
- Raul Teruel-Montoya,
- Lianchun Xiao,
- Sonia A. Melo,
- David Menter,
- Zhi-Qin Jiang,
- Elsa R. Flores,
- Massimo Negrini,
- Ajay Goel,
- Menashe Bar-Eli,
- Sendurai A. Mani,
- Chang Gong Liu,
- Gabriel Lopez-Berestein,
- Ioana Berindan-Neagoe,
- Manel Esteller,
- Scott Kopetz,
- Giovanni Lanza,
- George A. Calin
Affiliations
- Isidore Rigoutsos
- Computational Medicine Center, Sidney Kimmel Medical College at Thomas Jefferson University
- Sang Kil Lee
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center
- Su Youn Nam
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center
- Simone Anfossi
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center
- Barbara Pasculli
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center
- Martin Pichler
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center
- Yi Jing
- Computational Medicine Center, Sidney Kimmel Medical College at Thomas Jefferson University
- Cristian Rodriguez-Aguayo
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center
- Aristeidis G. Telonis
- Computational Medicine Center, Sidney Kimmel Medical College at Thomas Jefferson University
- Simona Rossi
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center
- Cristina Ivan
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center
- Tina Catela Ivkovic
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center
- Linda Fabris
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center
- Peter M. Clark
- Department of Pathology and Laboratory Medicine, The Children’s Hospital of Philadelphia
- Hui Ling
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center
- Masayoshi Shimizu
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center
- Roxana S. Redis
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center
- Maitri Y. Shah
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center
- Xinna Zhang
- Center for RNA interference and non-coding RNA, The University of Texas MD Anderson Cancer Center
- Yoshinaga Okugawa
- Center for Gastrointestinal Research, and Center for Translational Genomics and Oncology, Baylor Scott & White Research Institute and Charles A. Sammons Cancer Center, Baylor University Medical Center
- Eun Jung Jung
- Department of Surgery, School of Medicine, Gyeongsang National University
- Aristotelis Tsirigos
- Department of Pathology, NYU Langone Medical Center
- Li Huang
- Department of Cancer Biology, The University of Texas MD Anderson Cancer Center
- Jana Ferdin
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center
- Roberta Gafà
- Department of Morphology, Surgery and Experimental Medicine, University of Ferrara
- Riccardo Spizzo
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center
- Milena S. Nicoloso
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center
- Anurag N. Paranjape
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center
- Maryam Shariati
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center
- Aida Tiron
- Department of Medicine, Nassau University Medical Center
- Jen Jen Yeh
- Departments of Surgery and Pharmacology, UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
- Raul Teruel-Montoya
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center
- Lianchun Xiao
- Division of Quantitative Science, The University of Texas MD Anderson Cancer Center
- Sonia A. Melo
- i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, and Ipatimup - Institute of Pathology and Molecular Immunology of the University of Porto
- David Menter
- Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
- Zhi-Qin Jiang
- Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
- Elsa R. Flores
- Department of Molecular Oncology, Moffitt Cancer Center
- Massimo Negrini
- Department of Morphology, Surgery and Experimental Medicine, University of Ferrara
- Ajay Goel
- Center for Gastrointestinal Research, and Center for Translational Genomics and Oncology, Baylor Scott & White Research Institute and Charles A. Sammons Cancer Center, Baylor University Medical Center
- Menashe Bar-Eli
- Department of Cancer Biology, The University of Texas MD Anderson Cancer Center
- Sendurai A. Mani
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center
- Chang Gong Liu
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center
- Gabriel Lopez-Berestein
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center
- Ioana Berindan-Neagoe
- Research Center for Functional Genomics, Biomedicine and Translational Medicine
- Manel Esteller
- Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL)
- Scott Kopetz
- Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
- Giovanni Lanza
- Department of Medical Sciences, University of Ferrara
- George A. Calin
- Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center
- DOI
- https://doi.org/10.1186/s13059-017-1224-0
- Journal volume & issue
-
Vol. 18,
no. 1
pp. 1 – 21
Abstract
Abstract Background Non-coding RNAs have been drawing increasing attention in recent years as functional data suggest that they play important roles in key cellular processes. N-BLR is a primate-specific long non-coding RNA that modulates the epithelial-to-mesenchymal transition, facilitates cell migration, and increases colorectal cancer invasion. Results We performed multivariate analyses of data from two independent cohorts of colorectal cancer patients and show that the abundance of N-BLR is associated with tumor stage, invasion potential, and overall patient survival. Through in vitro and in vivo experiments we found that N-BLR facilitates migration primarily via crosstalk with E-cadherin and ZEB1. We showed that this crosstalk is mediated by a pyknon, a short ~20 nucleotide-long DNA motif contained in the N-BLR transcript and is targeted by members of the miR-200 family. In light of these findings, we used a microarray to investigate the expression patterns of other pyknon-containing genomic loci. We found multiple such loci that are differentially transcribed between healthy and diseased tissues in colorectal cancer and chronic lymphocytic leukemia. Moreover, we identified several new loci whose expression correlates with the colorectal cancer patients’ overall survival. Conclusions The primate-specific N-BLR is a novel molecular contributor to the complex mechanisms that underlie metastasis in colorectal cancer and a potential novel biomarker for this disease. The presence of a functional pyknon within N-BLR and the related finding that many more pyknon-containing genomic loci in the human genome exhibit tissue-specific and disease-specific expression suggests the possibility of an alternative class of biomarkers and therapeutic targets that are primate-specific.
Keywords